(Q53338014)

13 May 2018

title

Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. (English)

1 reference

13 May 2018

0 references

1 reference

2

1 reference

13 May 2018

author name string

van Os N

1

1 reference

13 May 2018

Bilo HJ

3

1 reference

13 May 2018

Casparie AF

4

1 reference

13 May 2018

van Hout BA

5

1 reference

13 May 2018

publication date

1 April 2000

1 reference

13 May 2018

published in

Health Policy

1 reference

13 May 2018

volume

51

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

135-147

1 reference

13 May 2018

Are we ready to use cost-effectiveness analysis in health care decision-making? A health services research challenge for clinicians, patients, health care systems, and public policy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Modelling in economic evaluation: an unavoidable fact of life

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Hyperglycemia and microvascular and macrovascular disease in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Model of complications of NIDDM. I. Model construction and assumptions.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

Is the incidence of diabetes increasing in all age-groups in The Netherlands? Results of the second study in the Dutch Sentinel Practice Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2800%2900063-4

7 January 2021

10.1016/S0168-8510(00)00063-4

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018